Shane Crotty, PhD

Scripps Research scientists and colleagues develop a nanodisc platform that offers a clearer view of how key viral proteins interact with antibodies.

Across four preclinical studies, Scripps Research, IAVI, and additional collaborators make headway in stimulating the rare antibodies needed to fight HIV.

Finding opens the door for new vaccine approaches and strategies.

The new method by scientists at Scripps Research identifies specific antibodies in immune responses to vaccination or infection in fraction of time needed for traditional approach.

A new approach that targets young immune cells may also work for creating vaccines against the flu, dengue, malaria and hepatitis C.

For more than 20 years, scientists at Scripps Research have chipped away at the challenges of designing an HIV vaccine. Now new research, published in Immunity, shows that their experimental vaccine strategy works in non-human primates.

Researchers found a transcription factor protein called Runx3 puts dividing T cells on track to becoming memory T cells. 

Researchers report the discovery that a protein called “Runx3” programs killer T cells to establish residence in tumors and infection sites.